title: Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profile.
abstract: There are currently no biological tests that differentiate patients with bipolar disorder (BPD) from healthy controls. While there is evidence that peripheral gene expression differences between patients and controls can be utilized as biomarkers for psychiatric illness, it is unclear whether current use or residual effects of antipsychotic and mood stabilizer medication drives much of the differential transcription. We therefore tested whether expression changes in first-episode, never-medicated BPD patients, can contribute to a biological classifier that is less influenced by medication and could potentially form a practicable biomarker assay for BPD. We employed microarray technology to measure global leukocyte gene expression in first-episode (n=3) and currently medicated BPD patients (n=26), and matched healthy controls (n=25). Following an initial feature selection of the microarray data, we developed a cross-validated 10-gene model that was able to correctly predict the diagnostic group of the training sample (26 medicated patients and 12 controls), with 89% sensitivity and 75% specificity (p<0.001). The 10-gene predictor was further explored via testing on an independent cohort consisting of three pairs of monozygotic twins discordant for BPD, plus the original enrichment sample cohort (the three never-medicated BPD patients and 13 matched control subjects), and a sample of experimental replicates (n=34). 83% of the independent test sample was correctly predicted, with a sensitivity of 67% and specificity of 100% (although this result did not reach statistical significance). Additionally, 88% of sample diagnostic classes were classified correctly for both the enrichment (p=0.015) and the replicate samples (p<0.001). We have developed a peripheral gene expression biomarker profile, that can classify healthy controls from patients with BPD receiving antipsychotic or mood stabilizing medication, which has both high sensitivity and specificity. Moreover, assay of three first-episode patients who had never received such medications, to first enrich the expression dataset for disease-related genes independent of medication effects, and then to test the 10-gene predictor, validates the peripheral biomarker approach for BPD.
authors.affiliation: Department of Pathology and Cell Biology, and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America. cc2786@columbia.edu
authors.forename: Catherine L
authors.initials: CL
authors.lastname: Clelland
authors.forename: Laura L
authors.initials: LL
authors.lastname: Read
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Panek
authors.forename: Robert H
authors.initials: RH
authors.lastname: Nadrich
authors.forename: Carter
authors.initials: C
authors.lastname: Bancroft
authors.forename: James D
authors.initials: JD
authors.lastname: Clelland
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000235:genetics; D016022:Case-Control Studies; D016002:Discriminant Analysis; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D008297:Male; D008957:Models, Genetic; D015203:Reproducibility of Results; D014430:Twins, Monozygotic / Q000235:genetics
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers